Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia

BACKGROUND: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanim, Farhat L., Hayden, Rachel E., Birtwistle, Jane, Lodi, Alessia, Tiziani, Stefano, Davies, Nicholas J., Ride, Jon P., Viant, Mark R., Gunther, Ulrich L., Mountford, Joanne C., Schrewe, Heinrich, Green, Richard M., Murray, Jim A., Drayson, Mark T., Bunce, Chris M.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785482/
https://www.ncbi.nlm.nih.gov/pubmed/19997560
http://dx.doi.org/10.1371/journal.pone.0008147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785482/
https://www.ncbi.nlm.nih.gov/pubmed/19997560
http://dx.doi.org/10.1371/journal.pone.0008147

Ejemplares similares